Viking Therapeutics Secures $575M for Obesity Drug Trials

Viking Therapeutics has successfully raised $575 million in gross proceeds through a combination of stock offerings and convertible senior notes. This significant capital infusion is earmarked to finance extensive Phase 3 clinical trials for VK2735, the company's promising GLP-1 and GIP agonist targeting obesity and type 2 diabetes. The funds will also support the development of Viking's broader drug pipeline, including an amylin agonist.

Currently, Viking is engaged in several large-scale trials for VK2735, both in subcutaneous and oral forms. Given the duration and scope of these trials, coupled with the company's lack of revenue, financial analysts project that Viking will continue to incur substantial costs through at least 2030. This recent financing provides essential runway for ongoing research and development activities.

The company's future success hinges significantly on the clinical performance of VK2735. Investors are keenly awaiting results from ongoing trials, with key data expected in 2027 and 2028. The substantial capital raised by Viking Therapeutics not only supports its ambitious clinical development program but also derisks the stock, empowering management to pursue value creation for its shareholders.